LPL Financial’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$858M Buy
3,945,266
+92,169
+2% +$20.4M 0.23% 93
2025
Q4
$880M Buy
3,853,097
+119,704
+3% +$27.3M 0.24% 91
2025
Q3
$864M Buy
3,733,393
+300,541
+9% +$61.2M 0.25% 86
2025
Q2
$637M Buy
3,432,852
+260,604
+8% +$48.4M 0.21% 100
2025
Q1
$665M Buy
3,172,248
+216,704
+7% +$42.1M 0.26% 86
2024
Q4
$525M Buy
2,955,544
+297,740
+11% +$54.7M 0.21% 104
2024
Q3
$525M Buy
2,657,804
+92,492
+4% +$17.3M 0.23% 94
2024
Q2
$440M Buy
2,565,312
+121,492
+5% +$20.1M 0.22% 98
2024
Q1
$445M Sell
2,443,820
-72,081
-3% -$12.4M 0.24% 93
2023
Q4
$390M Buy
2,515,901
+75,375
+3% +$11M 0.24% 94
2023
Q3
$364M Buy
2,440,526
+160,253
+7% +$23.5M 0.25% 90
2023
Q2
$307M Sell
2,280,273
-16,480
-0.7% -$2.42M 0.22% 99
2023
Q1
$366M Buy
2,296,753
+149,891
+7% +$22.9M 0.28% 77
2022
Q4
$347M Buy
2,146,862
+112,195
+6% +$17.2M 0.3% 74
2022
Q3
$273M Buy
2,034,667
+76,556
+4% +$11M 0.26% 84
2022
Q2
$300M Sell
1,958,111
-35,949
-2% -$5.49M 0.28% 73
2022
Q1
$323M Buy
1,994,060
+42,541
+2% +$6.18M 0.28% 68
2021
Q4
$264M Buy
1,951,519
+135,002
+7% +$15.9M 0.22% 90
2021
Q3
$196M Buy
1,816,517
+152,828
+9% +$17.5M 0.18% 107
2021
Q2
$187M Buy
1,663,689
+1,496
+0.1% +$168K 0.19% 104
2021
Q1
$180M Buy
1,662,193
+77,634
+5% +$8.3M 0.21% 102
2020
Q4
$170M Buy
1,584,559
+211,240
+15% +$20.3M 0.22% 92
2020
Q3
$120M Buy
1,373,319
+25,611
+2% +$2.41M 0.19% 107
2020
Q2
$132M Buy
1,347,708
+140,482
+12% +$12.4M 0.23% 90
2020
Q1
$92M Buy
1,207,226
+130,564
+12% +$11.1M 0.2% 97
2019
Q4
$95.3M Buy
1,076,662
+60,948
+6% +$5.06M 0.17% 110
2019
Q3
$76.9M Buy
1,015,714
+73,938
+8% +$5.07M 0.16% 123
2019
Q2
$68.5M Buy
941,776
+13,169
+1% +$1.04M 0.15% 125
2019
Q1
$74.8M Buy
928,607
+59,688
+7% +$4.88M 0.17% 117
2018
Q4
$80.1M Buy
868,919
+196,737
+29% +$17.3M 0.21% 96
2018
Q3
$63.6M Buy
672,182
+38,086
+6% +$3.61M 0.15% 124
2018
Q2
$58.7M Sell
634,096
-37,367
-6% -$3.65M 0.15% 125
2018
Q1
$63.6M Buy
671,463
+67,397
+11% +$7.4M 0.18% 109
2017
Q4
$58.4M Buy
604,066
+51,798
+9% +$4.88M 0.18% 110
2017
Q3
$49.1M Sell
552,268
-47,765
-8% -$3.64M 0.17% 113
2017
Q2
$43.5M Buy
600,033
+565,621
+1,644% +$38M 0.16% 120
2017
Q1
$2.24M Sell
34,412
-8,140
-19% -$512K 0.02% 771
2016
Q4
$2.66M Sell
42,552
-10,077
-19% -$615K 0.02% 657
2016
Q3
$3.32M Buy
52,629
+12,484
+31% +$808K 0.03% 526
2016
Q2
$2.52M Sell
40,145
-965,593
-96% -$58.8M 0.02% 642
2016
Q1
$58.9M Buy
1,005,738
+450,370
+81% +$25.1M 0.16% 130
2015
Q4
$31.9M Buy
555,368
+170,560
+44% +$9.82M 0.09% 210
2015
Q3
$21.8M Sell
384,808
-707
-0.2% -$46K 0.12% 158
2015
Q2
$26.3M Buy
385,515
+28,865
+8% +$1.88M 0.13% 153
2015
Q1
$20.4M Buy
356,650
+34,374
+11% +$2.08M 0.1% 177
2014
Q4
$21.1M Buy
322,276
+61
+0% +$3.85K 0.12% 168
2014
Q3
$18.4M Buy
322,215
+27,946
+9% +$1.55M 0.11% 181
2014
Q2
$16.6M Sell
294,269
-19,346
-6% -$1.01M 0.1% 191
2014
Q1
$16.1M Sell
313,615
-15,210
-5% -$769K 0.1% 193
2013
Q4
$17.4M Sell
328,825
-6,267
-2% -$308K 0.11% 178
2013
Q3
$15.5M Buy
335,092
+9,131
+3% +$405K 0.1% 180
2013
Q2
$13.5M Buy
+325,961
New +$14.3M 0.1% 186

Other funds holding ABBV

LPL Financial's ABBV Position: Q1 2026 in Review

LPL Financial increased its AbbVie (ABBV) stake by 2.4% in Q1 2026, buying an estimated $20.4M and bringing the position to 3,945,266 shares worth $858M. The position accounts for 0.23% of the portfolio, ranked #93.

LPL Financial first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $880M in Q4 2025. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • LPL Financial held 3,945,266 shares of AbbVie worth $858M as of Q1 2026.
  • LPL Financial bought 92,169 AbbVie shares in Q1 2026, an estimated $20.4M.
  • AbbVie made up 0.23% of LPL Financial's portfolio in Q1 2026, its #93 holding.
  • LPL Financial first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • LPL Financial's AbbVie position peaked at $880M in Q4 2025.
  • 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.